Although many guidelines do not endorse the incorporation of PD1/PD-L1 inhibitors into NAC, several studies have demonstrated that the integration of immunotherapy into NAC may enhance the efficacy of treatment for locally advanced gastric cancer. This evidence concerns the gene CD274 and gastric cancer.